FDA Regeneron Sanofi Eczema Drug – CWEB.com

sanofifda

FDA Regeneron Sanofi Eczema Drug – CWEB.com

FDA Approves Regeneron and Sanofi’s Dupixent for Eczema: Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers. The US Food and Drug Administration (FDA) today approved dupilumab (Dupixent, Regeneron Pharmaceutics), a biologic for patients with moderate to severe atopic dermatitis — also called eczema — that spares them from the need to resort to higher-risk systemic immunosuppressants.

 

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: